May 31, 2022
John H. Rex is a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. He is currently Chief Medical Officer for F2G, Ltd. (an antifungal biotech), an operating partner with a venture capital group (Advent Life Sciences), and Chair of the Scientific Advisory Board of the $1b AMR Action Fund. From 2015 to 2019, he was a voting member on the US Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB).
Dr. Rex’s experience includes moving compounds from preclinical development through all development phases via academic positions (NIH, Bethesda, MD; McGovern Medical School-Houston) and VP-level roles at a multinational pharmaceutical firm (AstraZeneca). Other past activities include advancing novel regulatory paradigms for antibacterials, publications on novel reimbursement models for antibiotics, co-founding of a public-private partnership (CARB-X), co-founding the New Drugs for Bad Bugs (ND4BB) program of Europe’s Innovative Medicines Initiative (IMI), and a four-year term as Industry Representative on the FDA Anti-Infective Drugs Advisory Committee (AIDAC, 2007 to 2011).